Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 11/20 | 0.43 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 5/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744771 | 1.00 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21806807 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20754366 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20744801 | 0.83 | BTK (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20744802 | 0.83 | BTK (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL864640 | 0.81 | BTK (0.56) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24005683 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21807324 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20754217 | 0.80 | ATG7 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24096712 | 0.79 | RET (0.45) | BTKLYNLCKIGF1RPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | Vyera Pharmaceuticals, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210347780-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2021-11-11 | — | — | US | disclosed |
| EP-3853230-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210032240-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2021-02-04 | — | — | US | disclosed |
| EP-3668875-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020061279-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019036001-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036001-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347780-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | CAMKK1, CAMK1, CAMKK2 | CYP1A2 4233/4885CYP3A4 3951/4885CYP2D6 4463/4885 |
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | CAMKK1, CAMK1, CAMKK2 | CYP1A2 4233/4885CYP3A4 3951/4885CYP2D6 4463/4885 |
| US-20210032240-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | CAMKK1, CAMK1, CAMKK2 | CYP1A2 4233/4885CYP3A4 3951/4885CYP2D6 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.